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Mucolipidosis II (Inclusion cell or I-cell disease) is an autosomal recessive lysosomal storage disorder clinically comparable to the mucopolysaccharidoses 
(MPS), characterized by progressive respiratory and neurologic deterioration. Sleep problems, especially obstructive sleep apnea (OSA) and disrupted 
sleep architecture, are observed in other lysosomal storage diseases but have not been described in mucolipidosis II. We report the progression 
of polysomnographic abnormalities in a child with mucolipidosis II, demonstrated by worsening sleep-related hypoventilation, OSA, and sleep state 
fragmentation despite advancing PAP therapy. Background slowing and reduction in spindle activity on limited EEG may reflect progressive CNS disease 
affecting thalamic neurons.
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INTRODUCTION
Mucolipidosis II (Inclusion-cell or I-cell disease) is a rare ly-
sosomal storage disorder with clinical features similar to the 
mucopolysaccharidoses (MPS), due to impaired intracellu-
lar enzymatic degradation of substrates and accumulation of 
these undigested substrates within cell bodies.1 Obstructive 
sleep apnea (OSA) and hypoventilation have been reported, 
presumably due to progressive airway obstruction and central 
nervous system disease as seen in MPS.2 Progression of OSA 
and disrupted sleep architecture have been described in MPS; 
however, details of polysomnography and clinical course of 
sleep abnormalities have not been previously characterized in 
mucolipidosis.3–6
REPORT OF CASE
We report a 15-year-old male with mucolipidosis II who is 
followed in our pediatric airway and sleep centers. When di-
agnosed at 19 months of age, he exhibited typical disease char-
acteristics including coarse facial features with a prominent 
forehead, short stature, kyphosis, and hepatomegaly. His dis-
ease course has been characterized by growth delay, recurrent 
otitis media and heart disease involving mild left ventricular 
hypertrophy and mild aortic/mitral valvular stenosis. Progres-
sive kyphoscoliosis led to multiple spinal surgeries during 
childhood. Polysomnography at 3 years of age revealed severe 
OSA with an apnea-hypopnea index (AHI) of 43 events per 
hour, nadir pulse oximetry of 70%, and maximum end-tidal 
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CO2 (ETCO2) of 60 torr. Flexible bronchoscopy demonstrated 
adenoid hypertrophy with diffuse upper and lower airway 
mucosal edema. Adenoidectomy was performed at 3.5 years 
of age and repeat polysomnography 10 months later demon-
strated residual sleep apnea, consisting of both obstructive and 
central events (AHI of 11.1, OAI of 5.0, and CAI of 1.9). The 
patient began continuous positive airway pressure (CPAP) at 5 
years of age. Because of respiratory irregularity with central 
apnea and hypoventilation on CPAP (AHI of 6.9, OAI of 1.3, 
CAI of 3.9 with maximum ETCO2 of 58 torr), he was transi-
tioned to bilevel positive airway pressure (BiPAP) with backup 
rate of 10 breaths/min at 10 years of age. Hypoventilation im-
proved as evidenced by reduction in awake and maximum 
sleep-related ETCO2, however these measures again worsened 
over the following years despite increasing ventilatory support 
(Figure 1A). Serial echocardiography revealed normal right 
ventricular function without pulmonary hypertension to ex-
plain the need for supplemental oxygen. Sleep architecture was 
consistently abnormal with poor sleep continuity, excessive 
state fragmentation, and REM duration < 15% of total sleep 
time. Sleep EEG was notable for paucity of sleep spindles, hy-
persynchronous slowing following arousals, and presence of 
background EEG slowing (Figure 1B).
DISCUSSION
This case demonstrates progression of multifactorial sleep dis-
turbance during childhood in mucolipidosis II, characterized 
by worsening OSA, hypoventilation and sleep architecture 
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changes. Apnea and hypoventilation worsened with advanc-
ing age, similar to what we observed in our cross-sectional 
study of mucopolysaccharidosis II.5 As in the mucopolysac-
charidoses, airway narrowing from soft-tissue deposits within 
the upper airway, along with craniofacial abnormalities such 
as flat face and depressed nasal bridge, are presumed to yield 
an increased risk of OSA. In lysosomal storage diseases, 
hypoventilation may also occur as a result of skeletal limi-
tations, lung parenchymal changes or central neural regula-
tory changes. Scoliosis and decreased thoracic elasticity may 
contribute to restrictive lung disease and reduced respiratory 
reserve during apneic episodes. An increasing gap between 
baseline and maximum ETCO2 suggests worsening sleep-
related hypoventilation, either from progression of primary 
pulmonary disease or a state-dependent central nervous pro-
cessing issue. The latter is supported by the presence of cen-
tral apnea despite elevated CO2.
Notable electroencephalographic changes were apparent in-
cluding reduction in sleep spindles and increase in background 
slowing on EEG (Figure 1). Background slowing was noted 
even during wakefulness, which may reflect thalamocortical 
dysfunction from the mucolipidosis. Despite the lack of clear 
structural changes on brain MRI, the absence of sleep spindles 
suggests dysfunction within thalamic neurons. This reduction 
of spindle activity during non-REM sleep is an unusual find-
ing, described in a few neurological disorders such as Parkin-
son disease and Lewy body dementia.
Our patient’s course suggests that sleep-related breathing 
disorder evolves through childhood in mucolipidosis II. Gas 
exchange alterations and disrupted sleep architecture may re-
flect cumulative effects upon the airway and central nervous 
system, while changes in sleep neural regulatory processes 
may be related to mucolipidosis II involvement of central 
neural regulatory pathways. Frequent clinical and PSG based 
monitoring is necessary in these patients to avoid secondary 
complications arising from sleep apnea and hypoventilation. 
Polygraphic sleep parameters also bear potential utility to indi-
cate therapeutic response as novel therapies become available 
for this category of disorders.
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Figure 1
(A) PSG findings of end-tidal CO2 (ETCO2) and respiratory support 
settings over time/age. Squares indicate ETCO2 measured at onset of 
PSG and maximum during sleep. Other symbols represent respiratory 
support settings used during PSG to control respiratory events. (B) 
Limited EEG montage during PSG in NREM sleep. Background 
slowing and paucity of sleep spindles suggest altered thalamocortical 
function and may be a consequence of disease deposits within 
thalamic neurons.
